225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

Volume: 46, Issue: 1, Pages: 129 - 138
Published: Jan 1, 2019
Abstract
A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naive patients with advanced metastatic prostate carcinoma. Seventeen patients with advanced prostate cancer were selected for treatment with 225Ac-PSMA-617 in 2-month intervals,...
Paper Details
Title
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Published Date
Jan 1, 2019
Volume
46
Issue
1
Pages
129 - 138
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.